Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab–irinotecan in children with low‐grade glioma?

The association of bevacizumab and irinotecan has been shown to display a quick efficacy in low‐grade glioma (LGG), but most patients relapse within months after cessation of therapy. From October 2012 to March 2014, four patients have been treated with irinotecan–bevacizumab followed by a metronomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Heng, Marie Amélie, Padovani, Laetitia, Dory‐Lautrec, Philippe, Gentet, Jean Claude, Verschuur, Arnaud, Pasquier, Eddy, Figarella‐Branger, Dominique, Scavarda, Didier, André, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944881/
https://www.ncbi.nlm.nih.gov/pubmed/27037940
http://dx.doi.org/10.1002/cam4.699
_version_ 1782442823983824896
author Heng, Marie Amélie
Padovani, Laetitia
Dory‐Lautrec, Philippe
Gentet, Jean Claude
Verschuur, Arnaud
Pasquier, Eddy
Figarella‐Branger, Dominique
Scavarda, Didier
André, Nicolas
author_facet Heng, Marie Amélie
Padovani, Laetitia
Dory‐Lautrec, Philippe
Gentet, Jean Claude
Verschuur, Arnaud
Pasquier, Eddy
Figarella‐Branger, Dominique
Scavarda, Didier
André, Nicolas
author_sort Heng, Marie Amélie
collection PubMed
description The association of bevacizumab and irinotecan has been shown to display a quick efficacy in low‐grade glioma (LGG), but most patients relapse within months after cessation of therapy. From October 2012 to March 2014, four patients have been treated with irinotecan–bevacizumab followed by a metronomic maintenance with weekly vinblastine to try to prevent relapses. After a median follow‐up of 23 months after the end of the bevacizumab–irinotecan induction, no patient relapsed. These observations suggest that maintenance chemotherapy with weekly vinblastine after an induction by irinotecan–bevacizumab can improve progression‐free survival in children with LGG.
format Online
Article
Text
id pubmed-4944881
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-49448812016-07-25 Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab–irinotecan in children with low‐grade glioma? Heng, Marie Amélie Padovani, Laetitia Dory‐Lautrec, Philippe Gentet, Jean Claude Verschuur, Arnaud Pasquier, Eddy Figarella‐Branger, Dominique Scavarda, Didier André, Nicolas Cancer Med Clinical Cancer Research The association of bevacizumab and irinotecan has been shown to display a quick efficacy in low‐grade glioma (LGG), but most patients relapse within months after cessation of therapy. From October 2012 to March 2014, four patients have been treated with irinotecan–bevacizumab followed by a metronomic maintenance with weekly vinblastine to try to prevent relapses. After a median follow‐up of 23 months after the end of the bevacizumab–irinotecan induction, no patient relapsed. These observations suggest that maintenance chemotherapy with weekly vinblastine after an induction by irinotecan–bevacizumab can improve progression‐free survival in children with LGG. John Wiley and Sons Inc. 2016-03-31 /pmc/articles/PMC4944881/ /pubmed/27037940 http://dx.doi.org/10.1002/cam4.699 Text en © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Heng, Marie Amélie
Padovani, Laetitia
Dory‐Lautrec, Philippe
Gentet, Jean Claude
Verschuur, Arnaud
Pasquier, Eddy
Figarella‐Branger, Dominique
Scavarda, Didier
André, Nicolas
Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab–irinotecan in children with low‐grade glioma?
title Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab–irinotecan in children with low‐grade glioma?
title_full Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab–irinotecan in children with low‐grade glioma?
title_fullStr Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab–irinotecan in children with low‐grade glioma?
title_full_unstemmed Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab–irinotecan in children with low‐grade glioma?
title_short Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab–irinotecan in children with low‐grade glioma?
title_sort can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab–irinotecan in children with low‐grade glioma?
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944881/
https://www.ncbi.nlm.nih.gov/pubmed/27037940
http://dx.doi.org/10.1002/cam4.699
work_keys_str_mv AT hengmarieamelie canmetronomicmaintenancewithweeklyvinblastinepreventearlyrelapseprogressionafterbevacizumabirinotecaninchildrenwithlowgradeglioma
AT padovanilaetitia canmetronomicmaintenancewithweeklyvinblastinepreventearlyrelapseprogressionafterbevacizumabirinotecaninchildrenwithlowgradeglioma
AT dorylautrecphilippe canmetronomicmaintenancewithweeklyvinblastinepreventearlyrelapseprogressionafterbevacizumabirinotecaninchildrenwithlowgradeglioma
AT gentetjeanclaude canmetronomicmaintenancewithweeklyvinblastinepreventearlyrelapseprogressionafterbevacizumabirinotecaninchildrenwithlowgradeglioma
AT verschuurarnaud canmetronomicmaintenancewithweeklyvinblastinepreventearlyrelapseprogressionafterbevacizumabirinotecaninchildrenwithlowgradeglioma
AT pasquiereddy canmetronomicmaintenancewithweeklyvinblastinepreventearlyrelapseprogressionafterbevacizumabirinotecaninchildrenwithlowgradeglioma
AT figarellabrangerdominique canmetronomicmaintenancewithweeklyvinblastinepreventearlyrelapseprogressionafterbevacizumabirinotecaninchildrenwithlowgradeglioma
AT scavardadidier canmetronomicmaintenancewithweeklyvinblastinepreventearlyrelapseprogressionafterbevacizumabirinotecaninchildrenwithlowgradeglioma
AT andrenicolas canmetronomicmaintenancewithweeklyvinblastinepreventearlyrelapseprogressionafterbevacizumabirinotecaninchildrenwithlowgradeglioma

Ejemplares similares